Eli Lil­ly and Roche ask CMS not to be lumped in with Aduhelm’s re­stric­tive judg­ment

With CMS clos­ing its pub­lic com­ment pe­ri­od for its draft de­ci­sion to lim­it cov­er­age of Bio­gen’s Aduhelm last week, two Big Phar­ma com­pa­nies de­vel­op­ing sim­i­lar Alzheimer’s drugs got in their com­ments just be­fore Thurs­day’s dead­line.

Eli Lil­ly and Roche both post­ed lengthy let­ters to the CMS site aim­ing to con­vince CMS to re­verse its rul­ing re­strict­ing Aduhelm cov­er­age to pa­tients in clin­i­cal stud­ies. The pair has a lot on the line as their own an­ti-amy­loid an­ti­bod­ies make their way through the FDA re­view pe­ri­od.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER